Major Holder Sells ~$198k of LAVA Therapeutics (LVTX) Stock
LAVA Therapeutics NV
Subscribe to track LVTX
Premium users can add ticker alerts and receive realtime notification updates.
Filing Summary
Major Holder Sells ~$198k of LAVA Therapeutics (LVTX) Stock
Company: LAVA Therapeutics NV (LVTX) Form: 4 | Filed: 2025-10-10 Significance: Medium
Insider: Cooperatieve Gilde Healthcare IV U.A. Title: null | Relationship: 10% Owner
Transaction (Aggregated over 3 days): • Type: Sell • Shares: 126,992 • Avg. Price: $1.56 • Value: $197,890 • Owned After: 5,294,178
Key Insight: A major institutional holder, Gilde Healthcare, conducted a series of sales over three consecutive days, disposing of over 126k shares. This consistent selling pressure from a >10% owner warrants attention.
Market Context: The sales were executed at prices between $1.53 and $1.62. As a healthcare-focused investment firm, this could represent profit-taking or portfolio rebalancing rather than a fundamental change in outlook on LVTX.
This is PUBLIC SEC data for educational purposes. Not investment advice.
Comprehensive Analysis
SEC Filing Analysis: LAVA Therapeutics NV (LVTX)
Executive Summary
- Trading Significance: Medium
- Key Takeaway: Gilde Healthcare, a greater than 10% owner, sold a total of 126,992 shares for approximately $198,000 over three consecutive days. This pattern of selling by a major institutional holder is a notable event.
- Market Impact: The consistent selling, though not massive in total value, could create short-term bearish sentiment or be interpreted as a strategic portfolio adjustment by the institutional owner.
Company Information
| Field | Value |
|---|---|
| Company | LAVA Therapeutics NV |
| Ticker Symbol | LVTX |
| CIK | 0001840748 |
| Industry | Pharmaceutical Preparations |
Insider Information
| Field | Value |
|---|---|
| Name | Cooperatieve Gilde Healthcare IV U.A. |
| CIK | 0001756335 |
| Title/Position | null |
| Relationship | 10% Owner |
Transaction Details
This filing reports three separate sale transactions on consecutive days.
| Field | Transaction 1 (Oct 8) | Transaction 2 (Oct 9) | Transaction 3 (Oct 10) |
|---|---|---|---|
| Transaction Date | 2025-10-08 | 2025-10-09 | 2025-10-10 |
| Transaction Code | S (Sale) | S (Sale) | S (Sale) |
| Shares Involved | 28,954 | 48,169 | 49,869 |
| Price Per Share | $1.57 (Avg) | $1.56 (Avg) | $1.55 (Avg) |
| Total Value | $45,459.78 | $75,143.64 | $77,296.95 |
Aggregated Transaction Summary:
| Field | Value |
|---|---|
| Form Type | 4 |
| Transaction Dates | 2025-10-08 to 2025-10-10 |
| Security Type | Common Shares |
| Total Shares Sold | 126,992 |
| Total Value | $197,890.37 |
| Shares Owned After | 5,294,178 |
| Ownership Type | Direct |
Market Impact Analysis
Stock Impact Prediction
- Direction: Neutral to Negative
- Reasoning: A sale by a >10% owner is often viewed as a bearish signal. However, given that the seller is a healthcare investment fund, these sales could be part of a standard portfolio rebalancing or profit-taking strategy, which would mitigate the negative signal. The total value is not large enough to cause a major price dislocation.
Volume & Sentiment
- Expected Volume Impact: Minor increase in trading volume around the dates of the transactions.
- Sentiment Indicator: Bearish. Open-market sales from insiders, especially large holders, tend to create negative sentiment among retail and institutional investors.
Investment Insights
Positive Market Indicators
- The insider still holds a very large position of over 5.2 million shares, indicating continued significant exposure to the company's future.
Risk Factors
- A pattern of consecutive daily sales from a major institutional holder can signal a decision to reduce exposure, which could precede negative news or simply a change in investment thesis.
- The sales occurred at a relatively low price point (~$1.56), which could be interpreted as the seller not expecting a significant near-term price appreciation.
Key Takeaways
- Consistent Selling: The sales were not a one-off event but a structured, multi-day disposition of shares.
- Institutional Holder: The seller is Gilde Healthcare, a specialized investment firm. Their actions may be driven by fund-level mandates (e.g., lifecycle, diversification) rather than a specific negative view on LVTX.
- Significant Remaining Stake: Despite the sales, Gilde Healthcare remains a top shareholder, retaining a vested interest in the company's success.
Contextual Analysis
Timing Significance
- The sales occurred over three consecutive trading days, suggesting a deliberate and planned reduction in the position. The filing was made promptly on the day of the last transaction.
Transaction Context
- According to footnotes in the filing, the reported prices are weighted averages. The sales on October 8th ranged from $1.56 to $1.62, on October 9th from $1.54 to $1.59, and on October 10th from $1.53 to $1.58.
- Footnote F2 clarifies the relationship: the shares are held by Cooperatieve Gilde Healthcare IV U.A., which is managed by Gilde Healthcare IV Management BV, which is owned by Gilde Healthcare Holding B.V. All entities are reporting persons.
Company Context
- LAVA Therapeutics is a clinical-stage biotechnology company. Investors should consider these sales in the context of the company's clinical trial progress, cash runway, and overall biotech market sentiment.
Risk Assessment
Risk Level: Medium
Risk Factors
- Signaling Risk: The market may interpret the sales as a lack of confidence from a knowledgeable major investor.
- Overhang Risk: The market may anticipate further sales from this insider, creating a potential
Get Real-Time Alerts
Join our community to receive instant notifications when high-significance filings are published
Important Disclaimer
This content is drawn from public SEC filings and may contain errors. It is for informational purposes only and is not investment, legal, or tax advice.
Nothing here is a recommendation to buy, sell, or hold any security. Do your own due diligence.